FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.
| PDUFA Date | Drug | Indication | Type | PoA |
|---|---|---|---|---|
| 2026-06-29 | — | hyperphosphatemia in patients | NDA | 87% |
PoA = estimated probability of approval from published base rates and live data. See the full PDUFA calendar →
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2025-06-28 | — | NDA | +11.3% | -29.9% | -31% |
A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for UNCY and 2 more tickers of your choice.
Create Free Account →